Stay updated on Gilead Sciences Press Releases

Sign up to get notified when there's something new on the Gilead Sciences Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Gilead Sciences Press Releases page

  1. Check
    4 days ago
    Change Detected
    Summary
    A new press release entry about Livdelzi® (Seladelpar) for PBC and Bulevirtide is added to the News Releases page, and an older entry about the 'Choose U' campaign is removed.
    Difference
    4%
    Check dated 2025-10-27T14:07:59.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    Update: Old items from August/September 2025 are removed and newer October 2025 press releases and conference data are added, signaling a fresh wave of timely medical news coverage.
    Difference
    89%
    Check dated 2025-10-20T12:14:51.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    Updates the press release from Q2 2025 results to Q3 2025 results with the new communication date and earnings release date.
    Difference
    75%
    Check dated 2025-10-13T07:19:40.000Z thumbnail image
  4. Check
    33 days ago
    Change Detected
    Summary
    The page now highlights a STEM education grant from the Gilead Foundation, replacing a prior regulatory update about Lenacapavir. The focus has shifted from regulatory news to philanthropy, with dates updated to September 25, 2025 and July 25, 2025 respectively.
    Difference
    74%
    Check dated 2025-09-29T02:55:11.000Z thumbnail image
  5. Check
    54 days ago
    Change Detected
    Summary
    Gilead Sciences has announced a significant partnership with PEPFAR to deliver Lenacapavir for HIV prevention, alongside launching a new campaign highlighting the experiences of people living with HIV. Additionally, Gilead has broken ground on a new manufacturing hub as part of its growth strategy.
    Difference
    79%
    Check dated 2025-09-07T13:36:27.000Z thumbnail image
  6. Check
    62 days ago
    Change Detected
    Summary
    The page now includes an update on the European Commission's authorization of Yeytuo® (Lenacapavir) for HIV prevention, replacing the previous information about Yeztugo® (Lenacapavir) being the first FDA-approved option.
    Difference
    82%
    Check dated 2025-08-31T11:34:46.000Z thumbnail image

Stay in the know with updates to Gilead Sciences Press Releases

Enter your email address, and we'll notify you when there's something new on the Gilead Sciences Press Releases page.